Pfizer (NYSE:PFE) Given New $30.00 Price Target at UBS Group

Key Points

• UBS raised Pfizer’s price target from $27 to $30 but kept a “neutral” rating; its target implies 2.58% downside from the share price cited in the report.
• Analyst sentiment is mostly cautious: MarketBeat reported a consensus “Hold” rating and an average price target of $29.29, though Scotiabank raised its target to $35 and maintained “sector outperform.”
• Pfizer beat quarterly estimates, reporting $0.87 in earnings per share and $16.58 billion in revenue, but revenue was nearly flat year over year as COVID-product sales declined.

Pfizer (NYSE:PFE - Get Free Report) had its price target lifted by UBS Group from $27.00 to $30.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm presently has a "neutral" rating on the biopharmaceutical company's stock. UBS Group's price objective suggests a potential downside of 2.58% from the stock's current price.

Several other equities analysts have also commented on the company. Guggenheim reissued a "buy" rating on shares of Pfizer in a report on Tuesday, October 13th. HSBC lifted their price target on Pfizer from $28.00 to $30.00 and gave the stock a "hold" rating in a report on Thursday, September 10th. JPMorgan Chase & Co. upped their price objective on Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a research report on Friday, October 9th. Scotiabank increased their price objective on Pfizer from $33.00 to $35.00 and gave the company a "sector outperform" rating in a report on Wednesday. Finally, Wall Street Zen lowered Pfizer from a "buy" rating to a "hold" rating in a research report on Saturday, October 10th. Five investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $29.29.

Pfizer Stock Up 2.6%

NYSE PFE traded up $0.79 on Wednesday, hitting $30.79. 50,576,436 shares of the stock were exchanged, compared to its average volume of 39,838,277. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. Pfizer has a fifty-two week low of $23.62 and a fifty-two week high of $31.06. The company has a market cap of $175.52 billion, a PE ratio of 40.52, a PEG ratio of 2.08 and a beta of 0.31. The company has a 50-day moving average price of $28.64 and a 200-day moving average price of $26.84.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating analysts' consensus estimates of $0.74 by $0.13. The business had revenue of $16.58 billion for the quarter, compared to analyst estimates of $15.85 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company's revenue was down .4% on a year-over-year basis. During the same period last year, the business earned $0.87 EPS. Sell-side analysts anticipate that Pfizer will post 2.94 EPS for the current fiscal year.

Institutional Trading of Pfizer

Several institutional investors and hedge funds have recently made changes to their positions in PFE. BlackRock Inc. grew its stake in shares of Pfizer by 6.3% in the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company's stock worth $12,754,464,000 after purchasing an additional 31,412,883 shares in the last quarter. State Street Corp increased its holdings in shares of Pfizer by 1.8% during the second quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company's stock valued at $7,394,749,000 after purchasing an additional 5,501,032 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Pfizer by 11.1% during the first quarter. Bank of New York Mellon Corp now owns 53,879,900 shares of the biopharmaceutical company's stock valued at $1,512,948,000 after purchasing an additional 5,364,929 shares in the last quarter. Bank of America Corp DE bought a new stake in shares of Pfizer during the second quarter valued at about $1,049,602,000. Finally, Dimensional Fund Advisors LP lifted its holdings in Pfizer by 0.8% in the first quarter. Dimensional Fund Advisors LP now owns 36,422,799 shares of the biopharmaceutical company's stock worth $1,022,606,000 after purchasing an additional 293,029 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer beat Q3 estimates, reporting adjusted earnings of $0.87 per share and revenue of $16.58 billion. It raised its 2026 revenue outlook to $62–$64 billion and adjusted EPS guidance to $2.95–$3.05, citing solid performance and cost-saving progress. Pfizer Q3 results and guidance
• Positive Sentiment: Growth beyond COVID is gaining traction: non-COVID products grew 7% operationally, while launched and acquired products rose 32%. Eliquis and oncology medicines were among the growth drivers, helping offset weaker pandemic-product sales. Long-term investor takeaways
• Positive Sentiment: Scotiabank raised its price target to $35 and maintained a “sector outperform” rating, signaling confidence in further potential gains. Scotiabank rating
• Neutral Sentiment: Analyst views remain mixed: Citigroup raised its target to $30 but kept a “neutral” rating, while RBC’s higher $28 target still sits below the current share price. This suggests some caution despite recent target increases. Citigroup rating
• Neutral Sentiment: CEO Albert Bourla is pursuing a larger role in the obesity-drug market, an opportunity that could support longer-term growth, but its commercial impact remains to be demonstrated. Pfizer’s obesity-market ambitions
• Negative Sentiment: COVID-product sales continued to fall, and overall quarterly revenue was nearly flat year over year. The ongoing decline keeps pressure on Pfizer to prove its newer portfolio can replace pandemic-era revenue and sustain growth. Reuters report on Pfizer’s outlook

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company's portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.